+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Merck KGaA Company Analysis

  • ID: 4462161
  • Company Profile
  • July 2020
  • 49 pages
  • Pharma Intelligence
  • Merck Group
The publisher explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
  • Overview: Merck KGaA’s sparse late-stage pipeline and exposure to generics mean an increased reliance on newly launched Mavenclad and Bavencio.
  • Key themes: [1] Initial launch of Mavenclad is exceeding expectations, with significant market share gains in the US and 5EU [2] A significant portion of Merck KGaA’s portfolio has lost patent protection, but the company is maintaining sales growth due to emerging markets such as China [3] Late-stage pipeline predominantly related to Bavencio label expansions, although bintrafusp alfa and tepotinib could see regulatory filings based on Phase II data.
Model updates (14 May 2020)
  • Mavenclad forecast adjusted lower due to market dynamics.
Model updates (5 March 2020)
  • Mavenclad forecast adjusted higher due to strong launch
  • Rebif forecast adjusted lower.
Model updates (14 November 2019)
  • Bavencio forecast adjusted lower due to sales performance and management guidance
  • Mavenclad forecast adjusted higher due to accelerating pace of sales ramp across all regions.
Model updates (8 August 2019)
  • Bavencio forecast adjusted lower due to trajectory of launch ramp and timing of supplemental approvals in renal cell carcinoma
  • Glucophage forecast adjusted higher due to strong growth in China
  • Mavenclad forecast adjusted higher due to strong launch in the US
  • Rebif forecast adjusted lower due to competition in the interferon market, as well as from oral dosage forms
  • Erbitux forecast adjusted higher in RoW due to addition to National Reimbursement Drug List in China, and lower in 5EU due to increased competition
  • Bintrafusp alfa forecast added
  • Tepotinib forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Notable Quotes & Important Topics
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll